Compare AbbVie Inc (ABBV) vs iShares MSCI Canada (TSX) (EWC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI Canada (TSX) — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while iShares MSCI Canada (TSX) trades at $57.76. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MSCI Canada (TSX) pays none. Which is the better fit depends on your goals.
| ABBV | EWC | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $59.46 |
52-Week Low | $184.85 | $45.86 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EWC trades at $58.06, up 0.5% with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings with RSI at 78.59 indicating potential overbought conditions. Recent news highlights Canada's widening trade surplus and economic policy developments, which may impact this Canada-focused ETF. A dividend of $0.28 is scheduled for June 2026.
Outlook remains cautiously optimistic given bullish technicals and positive economic indicators from Canada, though overbought RSI suggests near-term consolidation. Risks include trade policy uncertainty and macroeconomic shifts. Investors should weigh technical strength against valuation metrics pending further fundamental data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →
